FDA Approves GLP-1 pill, Foundayo, for Weight Loss

Health & LifestyleNews
310

Listen to article (english)

Translate to Spanish or other 102 languages!

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems.

This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-oral-glp-1-pill-foundayo-for-weight-loss

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Texas AG Opens New Medicaid Fraud Investigations Based on Newly Released Federal Data
Next article
Cold, Flu, or Allergies? Key Differences to Watch For

More Articles

DHR Health Recertified for Advanced Hip & Knee Replacements

DHR Health has once again earned The Joint Commission's Advanced Certification in Total Hip and Total Knee Replacement, reaffirming its commitment to providing high-quality, patient-centered orthopedic care to the Rio Grande Valley.

STHS Named to Newsweek’s America’s Greatest Midsize Workplaces for Women

The American workforce is more diverse than ever, with women helping lead that transformation. 

Study Points to High Blood Pressure as a Key Factor in Rising Heart Disease Rates

Heart disease is the leading cause of death in the United States according to the Journal of the American College of Cardiology. Its impact extends beyond biology, with social detriments such as food insecurity, socioeconomic status and education influencing outcomes.

Dysfunctional, Not Missing, Immune Cells Explain Skin Cancer Risk in Immunosuppressed Patients

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively.
- Advertisement -